Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death - PubMed (original) (raw)
Review
. 2003 Oct 20;22(47):7396-402.
doi: 10.1038/sj.onc.1206943.
Affiliations
- PMID: 14576847
- DOI: 10.1038/sj.onc.1206943
Review
Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death
Lori A Hazlehurst et al. Oncogene. 2003.
Abstract
The emergence of clinical drug resistance continues to be an obstacle for the successful treatment of cancer. Our current understanding of mechanisms associated with drug resistance has been ascertained by investigating drug-resistant models created by exposing a parental population to increasing concentrations of a cytotoxic. These unicellular drug-resistant models have been critical in elucidating drug-resistant mechanism and in some cases have aided in the identification of drug targets. However, these models do not address resistance mechanisms that contribute to de novo drug resistance. We propose that specific niches within the tumor microenvironment may provide a sanctuary for subpopulations of tumors cells that affords a survival advantage following initial drug exposure and may facilitate the acquisition of acquired drug resistance. More specifically, we propose that the bone marrow microenvironment is a sanctuary for hema-topoietic cancers. This review will focus on the bone marrow microenvironment and its role in conferring resistance to cytotoxics and physiological mediators of cell death.
Similar articles
- [Research advance on role of tumor microenvironment in mediating acquired drug resistance].
Ma XL, Xing H, Ma D. Ma XL, et al. Ai Zheng. 2007 Aug;26(8):923-6. Ai Zheng. 2007. PMID: 17697561 Review. Chinese. - The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
Meads MB, Hazlehurst LA, Dalton WS. Meads MB, et al. Clin Cancer Res. 2008 May 1;14(9):2519-26. doi: 10.1158/1078-0432.CCR-07-2223. Clin Cancer Res. 2008. PMID: 18451212 Review. - Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS. Hazlehurst LA, et al. Cancer Res. 2003 Nov 15;63(22):7900-6. Cancer Res. 2003. PMID: 14633719 - Integrin-mediated cell-matrix interactions for prosurvival and antiapoptotic signaling after genotoxic injury.
Cordes N. Cordes N. Cancer Lett. 2006 Oct 8;242(1):11-9. doi: 10.1016/j.canlet.2005.12.004. Epub 2006 Jan 31. Cancer Lett. 2006. PMID: 16448744 Review. - Overview of tumor cell chemoresistance mechanisms.
Gatti L, Zunino F. Gatti L, et al. Methods Mol Med. 2005;111:127-48. doi: 10.1385/1-59259-889-7:127. Methods Mol Med. 2005. PMID: 15911977 Review.
Cited by
- Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy.
Storch K, Cordes N. Storch K, et al. Chemother Res Pract. 2012;2012:319287. doi: 10.1155/2012/319287. Epub 2012 Jun 18. Chemother Res Pract. 2012. PMID: 22778951 Free PMC article. - Nuclear export of proteins and drug resistance in cancer.
Turner JG, Dawson J, Sullivan DM. Turner JG, et al. Biochem Pharmacol. 2012 Apr 15;83(8):1021-32. doi: 10.1016/j.bcp.2011.12.016. Epub 2011 Dec 20. Biochem Pharmacol. 2012. PMID: 22209898 Free PMC article. Review. - Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model.
Landowski TH, Gard J, Pond E, Pond GD, Nagle RB, Geffre CP, Cress AE. Landowski TH, et al. Mol Cancer Ther. 2014 Jun;13(6):1558-66. doi: 10.1158/1535-7163.MCT-13-0962. Epub 2014 Apr 16. Mol Cancer Ther. 2014. PMID: 24739392 Free PMC article. - Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype.
Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AK. Ma S, et al. Cell Rep. 2021 Feb 9;34(6):108726. doi: 10.1016/j.celrep.2021.108726. Cell Rep. 2021. PMID: 33567287 Free PMC article. - β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. Carbonell WS, et al. Cancer Res. 2013 May 15;73(10):3145-54. doi: 10.1158/0008-5472.CAN-13-0011. Epub 2013 May 3. Cancer Res. 2013. PMID: 23644530 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources